ReviewNeurology international2022

Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.

Gaurav Nepal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.